" class="no-js "lang="en-US"> Foghorn Therapeutics - Medtech Alert
Tuesday, August 19, 2025
Foghorn Therapeutics | Pharmtech Focus

Foghorn Therapeutics

About Foghorn Therapeutics

Foghorn Therapeutics

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Related Story

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

December 13 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics […]